EIR Biopharma, a preclinical biotechnology company developing in-licensed therapies for eye diseases, has withdrawn its plans for an initial public offering. The San Francisco-based company had filed with regulators in February 2026 to raise approximately $17 million through the sale of 3.8 million shares at a proposed price range of $4 to $5 per share.
The withdrawal removes the company’s planned offering from the near-term IPO pipeline, although the announcement did not disclose a reason for the decision.
Proposed IPO Structure
EIR Biopharma initially planned to raise $17 million by offering approximately 3.8 million shares. At the proposed price range of $4 to $5 per share, the transaction was structured as a relatively small public-market offering.
The company had intended to list on the NYSE American but had not selected a ticker symbol. Its proposed offering was tracked under the reference ticker EIRB.RC.
Kingswood Capital Markets was scheduled to serve as the sole bookrunner for the transaction.
Company Background and Development Focus
Founded in 2022 and headquartered in San Francisco, California, EIR Biopharma operates in the biotechnology sector, focusing on therapies for eye diseases.
The company describes its development strategy as centered on in-licensed treatments and remains at the preclinical stage. The available information does not identify specific drug candidates, therapeutic targets, clinical milestones, or development timelines.
Closing Insights
EIR Biopharma’s withdrawal marks the cancellation of its proposed $17 million IPO, which had been intended to provide the company with access to public-market capital. The decision leaves its planned NYSE American listing on hold, with no revised offering schedule or explanation for the withdrawal disclosed.
Investors will need to monitor whether the company pursues alternative financing opportunities, advances its preclinical development programs, or revisits a public offering in the future.